NYSE · Pharmaceutical Preparations
Pfizer Inc. (PFE)
Pfizer's next earnings date, recent SEC filings, insider trades and reported financials, with end-of-day prices. Every number carries its date and source.
Last close
$28.74
+0.19% 1 day+21.8% 52 weeks
As of Sep 28, 2026, end of day (IEX). Not a live quote.
PFE · one year of daily closes
Sep 25, 2025 to Sep 28, 2026 · end of day · IEX
Closing prices, split-adjusted, from trades on the IEX exchange (published the next trading day). Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Key facts
- 1-day change
- +0.19%
- From $28.69 the session before
- 52-week change
- +21.8%
- Close vs close ~252 sessions earlier
- 52-week range
- $23.69–$29.03
- Lowest and highest closing prices
- Market cap
- $163.8B
- Last close × shares outstanding (SEC)
- Revenue (TTM)
- $63.7B
- 12 months to Jun 28, 2026
- Net income (TTM)
- $4.3B
- 12 months to Jun 28, 2026
- Diluted EPS (TTM)
- $0.76
- 12 months to Jun 28, 2026
Financials: trailing twelve months from Pfizer’s reported US-GAAP figures, SEC EDGAR XBRL company facts, period ended Jun 28, 2026.
Recent SEC filings
- Aug 4, 202610-QQuarterly report for the period ended Jun 28, 2026
- Aug 4, 20268-KCurrent report: Earnings results
- Jun 18, 20268-KCurrent report: Regulation FD disclosure
- Jun 18, 20268-KCurrent report: Executive or director change
- May 5, 202610-QQuarterly report for the period ended Mar 29, 2026
- May 5, 20268-KCurrent report: Earnings results
- Apr 27, 20268-KCurrent report: Shareholder vote results
- Mar 12, 2026DEF 14AProxy statement for a shareholder meeting
Source: SEC EDGAR. Each line is written from the form type and the official 8-K item titles; open the filing for the full text. All PFE filings on EDGAR
Next earnings
~Nov 3, 2026Estimated
Past results were usually filed before the open
Estimated from past filing dates. Pfizer hasn't announced this date; Vero projects it from the rhythm of its past SEC filings, so treat it as approximate.
Insider activity (last 90 days)
- Open-market buys
- 3
- filings · 114,863 shares
- Open-market sales
- 1
- filing · 3,278 shares
- BOURLA ALBERTChairman & CEO, DirectorFiled Aug 12, 2026Purchase 38,000at $26.34 avg
- DAMICO JENNIFER B.SVP & ControllerFiled Aug 6, 2026Sale 3,278at $25.40 avg
- BLAYLOCK RONALD EDirectorFiled Aug 5, 2026Purchase 39,231at $25.46 avg
- Buckley Mortimer JDirectorFiled Aug 5, 2026Purchase 37,632at $25.52 avg
Source: SEC EDGAR Form 4, filed in the 90 days to Oct 1, 2026. Counts are filings with at least one open-market purchase (P) or sale (S); grants, option exercises, tax withholding and gifts are left out.
Insider share counts and prices are as reported on Form 4.
With a free Vero account
What Vero tracks about Pfizer
Each new Pfizer filing and headline, summarized in plain English and scored 1–10 for how much it matters. Write down why you own PFE, and Vero reads every new item against those reasons: confirms, challenges or breaks. Alerts say when something crosses the line you set.
Pfizer (PFE): questions, answered from the data
When is Pfizer's next earnings date?
What was PFE's last closing price?
Have Pfizer insiders bought or sold shares recently?
What did Pfizer file with the SEC most recently?
Is this page a recommendation to buy or sell PFE?
Related by SEC industry code
- ABBVAbbVie Inc.$266.30+0.76%
- BMYBristol-Myers Squibb Company$63.88+1.57%
- JNJJohnson & Johnson$272.03+0.31%
- LLYEli Lilly and Company$1,185.54+0.13%
- MRKMerck & Co., Inc.$148.69−0.05%
- LINLinde plc$472.06+0.49%
Closes are end of day (IEX), as of each page’s date. Grouped by SEC industry code (SIC).
Prices: IEX HIST end-of-day bars, published the next trading day; never live. Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Filings, Form 4 and financials: Source: SEC EDGAR. Earnings dates: Vero’s calendar, marked confirmed or estimated.
Vero is a research tool, not a financial adviser. Nothing on this site is financial advice or a recommendation to buy or sell any security.
Data as of Oct 1, 2026.